Bharat Biotech's Covaxin phase 3 data shows 77.8 pc efficacy against COVID-19, says Lancet
Nov 12, 2021
Hyderabad (Telangana) [India], November 12 : Hyderabad-based Bharat Biotech on Friday announced that the Lancet peer-review confirmed the efficacy analysis of Bharat Biotech's Covaxin.